430 related articles for article (PubMed ID: 28478396)
1. UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice.
Lee AY; Lee CS; Egan CA; Bailey C; Johnston RL; Natha S; Hamilton R; Khan R; Al-Husainy S; Brand C; Akerele T; Mckibbin M; Downey L; Tufail A
Br J Ophthalmol; 2017 Dec; 101(12):1683-1688. PubMed ID: 28478396
[TBL] [Abstract][Full Text] [Related]
2. Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study.
Augsburger M; Sarra GM; Imesch P
Graefes Arch Clin Exp Ophthalmol; 2019 Sep; 257(9):1889-1895. PubMed ID: 31256237
[TBL] [Abstract][Full Text] [Related]
3. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
[TBL] [Abstract][Full Text] [Related]
4. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
[TBL] [Abstract][Full Text] [Related]
5. Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat-and-extend compared with pro re nata in eyes with neovascular age-related macular degeneration.
Aurell S; Sjövall K; Paul A; Morén Å; Granstam E
Acta Ophthalmol; 2019 Aug; 97(5):519-524. PubMed ID: 30511374
[TBL] [Abstract][Full Text] [Related]
6. A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom.
Johnston RL; Carius HJ; Skelly A; Ferreira A; Milnes F; Mitchell P
Adv Ther; 2017 Mar; 34(3):703-712. PubMed ID: 28144918
[TBL] [Abstract][Full Text] [Related]
7. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Continued Ranibizumab Therapy in Neovascular Age-Related Macular Degeneration versus Switch to Aflibercept: Real World Evidence.
Chakravarthy U; Bezlyak V; Sagkriotis A; Griner R; Skelly A; Boyer DS; Milnes F
Ophthalmol Retina; 2019 Jan; 3(1):8-15.e1. PubMed ID: 30929819
[TBL] [Abstract][Full Text] [Related]
9. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Ng P; Pecheur FL; McAllister IL
JAMA Ophthalmol; 2019 Apr; 137(4):372-379. PubMed ID: 30676617
[TBL] [Abstract][Full Text] [Related]
10. Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy.
Ricci F; Parravano M; Regine F; Sciamanna M; Tedeschi M; Missiroli F; Varano M
Eye (Lond); 2016 Aug; 30(8):1077-83. PubMed ID: 27229701
[TBL] [Abstract][Full Text] [Related]
11. Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set.
Lotery A; Griner R; Ferreira A; Milnes F; Dugel P
Eye (Lond); 2017 Dec; 31(12):1697-1706. PubMed ID: 28731052
[TBL] [Abstract][Full Text] [Related]
12. Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia.
Jaki Mekjavić P; Gregorčič B; Oberč C; Podgoršek S
BMC Ophthalmol; 2018 Dec; 18(1):333. PubMed ID: 30572850
[TBL] [Abstract][Full Text] [Related]
13. One- and two-year visual outcomes from the Moorfields age-related macular degeneration database: a retrospective cohort study and an open science resource.
Fasler K; Moraes G; Wagner S; Kortuem KU; Chopra R; Faes L; Preston G; Pontikos N; Fu DJ; Patel P; Tufail A; Lee AY; Balaskas K; Keane PA
BMJ Open; 2019 Jun; 9(6):e027441. PubMed ID: 31230012
[TBL] [Abstract][Full Text] [Related]
14. Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies.
Lanzetta P; Cruess AF; Cohen SY; Slakter JS; Katz T; Sowade O; Zeitz O; Ahlers C; Mitchell P
Acta Ophthalmol; 2018 Dec; 96(8):e911-e918. PubMed ID: 29659183
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab.
Elwes F; Borooah S; Aspinall P; Sim PY; Loo CY; Armbrecht AM; Dhillon B; Cackett P
BMC Ophthalmol; 2018 Jan; 18(1):20. PubMed ID: 29378528
[TBL] [Abstract][Full Text] [Related]
16. Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration.
Kvannli L; Krohn J
Acta Ophthalmol; 2017 Nov; 95(7):678-682. PubMed ID: 28139082
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration.
Abdin AD; Suffo S; Asi F; Langenbucher A; Seitz B
Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1671-1677. PubMed ID: 31144055
[TBL] [Abstract][Full Text] [Related]
18. Predictors of Outcome in Patients with Neovascular Age-Related Macular Degeneration Switched from Ranibizumab to 8-Weekly Aflibercept.
Chatziralli I; Nicholson L; Vrizidou E; Koutsiouki C; Menon D; Sergentanis TN; Citu MC; Hamilton R; Patel PJ; Hykin P; Sivaprasad S
Ophthalmology; 2016 Aug; 123(8):1762-1770. PubMed ID: 27289179
[TBL] [Abstract][Full Text] [Related]
19. Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden.
Panchmatia HR; Clements KM; Hulbert E; Eriksson M; Wittrup-Jensen K; Nilsson J; Weinstein MC
Acta Ophthalmol; 2016 Aug; 94(5):441-8. PubMed ID: 27061020
[TBL] [Abstract][Full Text] [Related]
20. UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) Users Group Report IV: Incidence of Blindness and Sight Impairment in Ranibizumab-Treated Patients.
Johnston RL; Lee AY; Buckle M; Antcliff R; Bailey C; McKibbin M; Chakravarthy U; Tufail A;
Ophthalmology; 2016 Nov; 123(11):2386-2392. PubMed ID: 27615601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
